INDICATIONS AND USAGE（适应症）

ALIQOPA is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

DOSAGE（服用剂量）

Recommended Dosage

The recommended dose of ALIQOPA is 60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Continue treatment until disease progression or unacceptable toxicity.

ADVERSE REACTIONS（不良反应）

Infections

Hyperglycemia

Hypertension

Non-infectious pneumonitis

Neutropenia

Severe cutaneous reactions

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/ade50241-2c10-4038-b4e9-72f6bf905f03/spl-doc?hl=Aliqopa

Aliqopainformation